Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > BioNanomatrix Wins NIH Funds to Commercialize its Whole Genome Platform

Abstract:
New Grants of $833,490 Bring NHGRI Phase II Support for Commercial Development of the Company's NanoAnalyzerŪ Imaging and Analysis Platform to Over $2.8 Million

Support Planned Initiation of Beta Site Testing in Second Quarter of 2010

BioNanomatrix Wins NIH Funds to Commercialize its Whole Genome Platform

Philadelphia, PA | Posted on October 15th, 2009

BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced receipt of two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The funding is intended to support further commercial development of BioNanomatrix's nanoscale whole genome imaging and analysis platform. BioNanomatrix plans to use the funds to prepare for the upcoming beta site launch of its first commercial NanoAnalyzerŪ system, planned for the second quarter of 2010.

BioNanomatrix is applying its nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual ultra-long strands of DNA in a massively parallel format. The benchtop system, currently in alpha evaluation, is designed to allow researchers to scan a human genome in as little as 10 minutes, creating an organizational map of each sample.

Researchers at beta sites plan to evaluate the instrument for a wide range of applications, from genome integrity to structural variation mapping. Advanced applications, including epigenetic mapping and sequence analysis, will be added later in development.

"This new funding from NHGRI provides additional support as we ramp up for initiation of beta site testing of our first commercial NanoAnalyzer systems, planned for the second quarter of the new year," said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix. "Our nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs, yielding a great deal of genomic information. We are, in essence, providing an imaging tool for genome analysis linking high-resolution sequence data with clinically important structural data in an easy-to-use and highly accessible way. We believe our technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, and we are very pleased that NHGRI is continuing to support our progress towards commercialization."

These two new supplemental grants bring the total that BioNanomatrix has been awarded under the Phase II NHGRI grant program to more than $2.8 million. These grants are part of a Small Business Innovation Research (SBIR) program, awarded under the NIH BECON II nanotech initiative, an interdisciplinary, multi-institutes consortium. BioNanomatrix is also the co-recipient of an $8.8 million multi-year grant from the U.S. National Institute of Standards and Technology Advanced Technology Program (NIST-ATP) to develop a system capable of sequencing the human genome in eight hours at a cost of less than $100.

####

About BioNanomatrix
BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in biomedical research, genetic diagnostics and personalized medicine. The company’s platform technology is designed to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs. This technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, providing fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information. Its current development efforts include a NIST-ATP funded project to sequence the human genome at a cost of $100. The company also receives funding from the National Institutes of Health. BioNanomatrix’s technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania.

For more information, please click here

Contacts:
Barbara Lindheim
GendeLLindheim BioCom Partners LLC
48 Wall Street, suite 1100
New York, NY 10005
212.918.4650 (office)
917.355.9234 (mobile)
www.biocompartners.com

Copyright © BioNanomatrix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

Photon recycling – The key to high-efficiency perovskite solar cells January 14th, 2022

NSF funds Rice effort to measure, preserve quantum entanglement: Physicist Guido Pagano wins CAREER Award to develop tools for quantum computing January 14th, 2022

Tuning the bonds of paired quantum particles to create dissipationless flow: A tunable platform made from atomically thin materials may help researchers figure out how to create a robust quantum condensate that can flow without losing energy January 14th, 2022

Possible Futures

Towards high-performance organic optoelectronics with better crystallinity at semiconductor interface: Organic molecular interfaces with minimized structural mismatch and spontaneous electron transfer could open doors to high-efficiency optoelectronics January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

The free-energy principle explains the brain January 14th, 2022

Nanomedicine

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

Preserving the goods: A new technique for isolating intact lysosomes from cell cultures: Scientists advance the study of fragile digestive organelles by developing strategy to rapidly extract them from cells using magnetic nanoparticles January 7th, 2022

Announcements

Nanostructures get complex with electron equivalents: Nanoparticles of two different sizes break away from symmetrical designs January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

The free-energy principle explains the brain January 14th, 2022

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

NSF funds Rice effort to measure, preserve quantum entanglement: Physicist Guido Pagano wins CAREER Award to develop tools for quantum computing January 14th, 2022

Nanostructures get complex with electron equivalents: Nanoparticles of two different sizes break away from symmetrical designs January 14th, 2022

Nanotube fibers stand strong -- but for how long? Rice scientists calculate how carbon nanotubes and their fibers experience fatigue December 24th, 2021

Record-breaking hole mobility heralds a flexible future for electronics: Researchers from The University of Tsukuba grow a germanium thin film on a flexible polyimide substrate, resulting in a material with the highest hole mobility reported to date December 24th, 2021

Nanobiotechnology

Bioengineered nanoparticles show promise for fibrinogen manufacture, says Journal of Pharmaceutical Analysis study: Scientists engineer a nanoparticle polymer that can selectively bind to fibrinogen in human plasma, presenting a pathway for improved drug development January 14th, 2022

New photonic effect could speed drug development: Twisted semiconductor nanostructures convert red light into the twisted blue light in tiny volumes, which may help develop chiral drugs January 14th, 2022

UT Southwestern develops nanotherapeutic to ward off liver cancer January 14th, 2022

Preserving the goods: A new technique for isolating intact lysosomes from cell cultures: Scientists advance the study of fragile digestive organelles by developing strategy to rapidly extract them from cells using magnetic nanoparticles January 7th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project